Dermatology and Hair Restoration: Where One Ends, One Begins

Introduction: A Shared Patient, Not a Rivalry

When people search for “dermatology and hair restoration,” many expect to find a rivalry. They want a scorecard: which doctor is more qualified, which specialty “owns” hair loss, and whether choosing one means rejecting the other. That framing misunderstands how good hair loss care actually works.

Hair loss treatment is rarely a single visit to a single specialist. It is a sequential pathway with two distinct phases of expertise. Dermatology diagnoses, rules out disease, and medically stabilizes the scalp. Hair restoration specialists then execute structural and surgical correction once a diagnosis confirms that a patient is a good candidate.

This distinction matters for nearly everyone. Androgenetic alopecia (AGA), the most common form of hair loss, affects up to 80% of men and 50% of women by age 70, according to epidemiological research published in PLOS ONE. In the United States alone, that represents roughly 50 million men and 30 million women. Most readers will, at some point, need to understand both halves of this pathway.

This article maps the actual clinical handoff between the two fields. It is not a guide to choosing one provider over another; it is a guide to knowing who is needed, and when.

Why This Question Confuses People in the First Place

Hair loss has many causes. Some are medical and reversible. Others are structural and permanent. Because the problem spans both categories, no single specialty owns all of it.

The landscape has grown more confusing with the rise of direct-to-consumer telehealth platforms. The hair loss telehealth market is projected to more than double between 2026 and 2030, growing at nearly 22% per year. These services often offer fast prescribing through an app or questionnaire, sometimes without a full diagnostic workup. That convenience blurs the line between self-diagnosis and genuine medical evaluation.

The risk is real. Skipping proper diagnosis can mean missing:

• Scarring alopecias, which permanently destroy follicles if left untreated
• Active alopecia areata, an autoimmune condition requiring specific medical management
• Reversible causes, such as thyroid dysfunction or iron deficiency

Each of these changes what “treatment” should even mean. The sections below provide a clear map of who does what, and when, in a properly sequenced care pathway.

Stage One: What Dermatology Diagnoses, Rules Out, and Treats Medically

For any new or worsening hair loss, dermatology is the correct first point of contact. This step comes before any discussion of surgical options.

A 2023 clinical review in the Journal of the American Academy of Dermatology (JAAD) outlines the diagnostic standard: a thorough history, a scalp and hair examination, trichoscopy, and, when the diagnosis is in doubt, laboratory analysis and biopsy.

Through this process, dermatologists distinguish androgenetic alopecia from conditions that look similar but behave very differently, including:

• Telogen effluvium, a temporary shedding often triggered by stress, illness, or hormonal change
• Alopecia areata, an autoimmune form of hair loss
• Scarring (cicatricial) alopecias, such as lichen planopilaris, frontal fibrosing alopecia, and central centrifugal cicatricial alopecia (CCCA)

Trichoscopy: The First Diagnostic Tool

Trichoscopy is dermoscopy applied to the scalp and hair. JAAD describes it as “an essential part of the hair loss consultation.” Using magnification, a clinician can visualize follicular patterns, signs of miniaturization (the progressive shrinking of hair follicles typical of pattern loss), and markers of scarring. This allows different disease types to be distinguished without invasive testing, and it often determines whether further workup is needed.

Scalp Biopsy: Resolving Diagnostic Uncertainty

When trichoscopy and examination leave questions unanswered, a biopsy provides clarity. JAAD guidance states that a biopsy should be performed whenever the diagnosis is in doubt or to assess the prognosis for regrowth at a given site. The standard approach is typically a 4-mm punch biopsy.

Biopsy is especially important for scarring alopecias. In these cases, the sample should be taken from an area of active inflammation to confirm whether the disease is still active.

There is also a significant equity consideration. Clinical guidance recommends that all female patients with Afrotextured hair being considered for central-scalp transplantation should have a biopsy first to rule out CCCA. When biopsied, CCCA is frequently identified in this population, and research notes that persons of African heritage often present with multiple concurrent forms of hair loss, both scarring and nonscarring. Without a biopsy, a transplant could be placed into scalp tissue affected by an active scarring process.

Bloodwork and Reversible Causes

Laboratory panels help identify conditions that can mimic or worsen pattern hair loss, including:

• Thyroid dysfunction
• Iron or ferritin deficiency
• Hormonal imbalance

These causes are often reversible with medical management alone. Ruling them out protects patients from pursuing a structural solution to a non-structural problem.

Medical and Pharmaceutical Therapy, Including JAK Inhibitors

Once a condition is diagnosed, dermatologists draw on a toolkit of topical and oral therapies to manage it. For pattern hair loss, this often includes medications such as minoxidil and finasteride.

For autoimmune alopecia areata, treatment has advanced considerably. According to the National Alopecia Areata Foundation, the FDA approved three JAK inhibitors between 2022 and 2023:

• Baricitinib (Olumiant)
• Ritlecitinib (Litfulo)
• Deuruxolitinib (Leqselvi)

These systemic treatments are prescribed and monitored by dermatologists. They fall outside the scope of hair restoration surgery. Baricitinib received FDA approval for adolescent use in September 2026, and real-world data show that roughly 63% of patients with severe alopecia areata achieved significant improvement at 48 weeks.

The key point is straightforward: active alopecia areata under treatment is not something a transplant can address. It requires ongoing dermatologic management first.

Stage Two: Confirming Surgical Candidacy

Once a dermatologist has diagnosed the condition and confirmed it is stable, meaning there is no active autoimmune or inflammatory disease, a new question emerges: is structural correction appropriate?

An international expert consensus published in the Journal of Dermatological Treatment sets the standard. Hair loss should be stable for 6 to 12 months, and patients under 30 should typically trial medical therapy (finasteride and/or minoxidil) before any surgical referral.

This is not a formality. It is a clinical safeguard against operating on tissue that is still actively changing. Transplanting into a scalp whose pattern of loss has not yet declared itself can produce results that look unnatural as surrounding hair continues to thin.

Contraindications a Dermatologist Must Rule Out First

Recognized medical contraindications to hair transplant surgery include:

1. Active or unstable scarring alopecia
2. Active alopecia areata
3. Diffuse unpatterned alopecia (DUPA)

Scarring alopecias and alopecia areata often require 6 to 24 months of confirmed quiescence before a transplant can even be considered. No reputable hair restoration specialist should operate without this dermatologic clearance. This is precisely where the two fields depend on each other rather than compete.

The DPA vs. DUPA Distinction in Women

In women, the single biggest gatekeeper for surgical candidacy is the distinction between two patterns:

• Diffuse patterned alopecia (DPA): Thinning in the top and front of the scalp, with a stable donor zone at the back and sides
• Diffuse unpatterned alopecia (DUPA): Thinning that also affects the donor zone, leaving no reliable source of grafts

More than 50% of women with diffuse hair loss present with DUPA and are therefore not transplant candidates. Overall, only about 2 to 5% of women with hair loss are true surgical candidates, compared with roughly 90% of balding men.

This gap explains why dermatologic evaluation is especially critical before any woman considers surgery. And the DPA versus DUPA distinction cannot be made reliably through visual assessment alone; it requires proper diagnostic workup, including trichoscopic evaluation of the donor area.

Stage Three: What Only a Hair Restoration Specialist Can Execute

The handoff point is precise. Once disease has been ruled out or confirmed stable, and candidacy criteria are met, the pathway moves from medical management to structural, surgical, or cosmetic correction.

This is a distinct skill set, neither lesser than diagnosis nor superior to it, but a different discipline requiring its own specialized training, artistic judgment, and extensive repetition.

Surgical Options: FUE and FUT

Two primary surgical techniques form the foundation of modern hair restoration:

• FUE (Follicular Unit Extraction): A minimally invasive technique in which individual follicles are extracted one at a time and transplanted. It is known for minimal visible scarring and a faster recovery.
• FUT (Follicular Unit Transplantation, or strip surgery): A strip of donor tissue is removed and dissected under microscopes into individual follicular units. FUT is often better suited for women and can yield larger graft sessions. It is sometimes combined with FUE to achieve maximum graft counts.

Both are structural, mechanical solutions. They are appropriate only after medical causes have been excluded or stabilized, and they are never substitutes for diagnosis.

Non-surgical cosmetic options, such as scalp micropigmentation (SMP), also fall within the hair restoration specialist’s domain. SMP creates the appearance of fuller, denser hair and can serve patients who are not surgical candidates or complement a surgical result.

Why Credentialing Matters More in This Field, Not Less

There is no board certification for “hair restoration surgery” recognized by the American Board of Medical Specialties (ABMS). In practical terms, any licensed physician can legally perform a hair transplant, regardless of training background.

Voluntary credentialing bodies fill this gap:

• ABHRS (American Board of Hair Restoration Surgery), founded in 1996
• ISHRS (International Society of Hair Restoration Surgery) membership and fellowship credentials

True specialization is rare. Only about 270 surgeons worldwide hold ABHRS Diplomate status, fewer than 23% of the more than 1,200 ISHRS members.

Volume matters, too. The average ISHRS-member surgeon performs only about 178 to 180 procedures per year. For patients, this reinforces why exclusive focus on hair restoration, rather than transplants offered as one of many services, is meaningful for surgical skill and consistency.

The Overlap Zone: Where Both Fields Use the Same Tools

Not every therapy belongs exclusively to one side of the pathway. Some treatments are used by both dermatologists and hair restoration specialists.

Platelet-rich plasma (PRP) is a prime example. PRP uses concentrated growth factors from a patient’s own blood to support follicle health. Meta-analyses show moderate density gains, roughly 25 to 35 hairs per square centimeter in some reviews, with patient satisfaction around 78 to 92%.

PRP is frequently combined with minoxidil for a synergistic effect. One randomized controlled trial found a 32% greater density increase with PRP plus minoxidil compared with minoxidil alone.

This overlap does not blur the line between diagnosis and surgery. It simply shows that maintenance and optimization can be collaborative across the care team, even after the initial handoff. A patient who undergoes a transplant may continue medical therapy and regenerative treatments to protect native hair for years afterward.

Why Getting the Sequence Wrong Costs Patients Time and Results

Skipping dermatologic evaluation carries real consequences. Pursuing a transplant before ruling out active alopecia areata, unstable scarring alopecia, or DUPA can lead to poor graft survival, continued loss around transplanted areas, or even harm to the scalp itself.

The diagnostic side of the field is also evolving digitally. The online dermatology consultation market is projected to more than triple between 2026 and 2035. Virtual care improves access, but it also makes in-person trichoscopic evaluation, and biopsy when necessary, even more essential before a patient commits to any irreversible step.

Proper sequencing is not bureaucracy. A patient’s donor supply is finite. Every graft harvested is a graft that cannot be harvested again. Sequencing protects that donor supply, the health of the scalp, and the long-term outcome before surgical decisions are made.

A Collaborative Care Model: How Shapiro Medical Group Fits Into the Pathway

Shapiro Medical Group, based in Minneapolis, Minnesota, has focused exclusively on hair transplantation for more than 30 years. Within the care pathway described above, the practice represents the surgical second half of the team. It is not a replacement for dermatologic diagnosis.

SMG’s physicians, including Dr. Ron Shapiro, co-author of the field’s leading hair transplant textbook, and FUE Director Dr. David Josephitis, operate on patients once a diagnosis points toward structural correction and candidacy has been confirmed. All physicians at the practice are board-certified, and the medical team has lectured at more than 100 conferences in over 20 countries.

Two features of the practice reflect its surgical specialization:

• A one-patient-per-day policy, which gives each patient the full, undivided attention of the surgical team
• Combined FUE and FUT capabilities, allowing the team to tailor graft harvesting to each patient’s donor characteristics and goals

These features complement, rather than compete with, the diagnostic work already completed by a dermatologist. The practice also offers non-surgical options, including SMP, regenerative therapies, and medical therapies to maintain hair growth over time.

SMG’s position within the broader medical community is reinforced by an unusual distinction: physicians from other practices travel to the clinic both to learn advanced techniques and to have their own procedures performed. The practice welcomes collaboration with referring dermatologists and physicians, functioning as part of a larger care team rather than as a standalone alternative to medical evaluation.

Conclusion: One Pathway, Two Essential Specialists

Hair loss care follows a sequential model. Dermatology diagnoses, rules out disease, and stabilizes medically treatable conditions. Hair restoration specialists execute structural correction once candidacy is confirmed. Long-term maintenance often involves both.

This is not a rivalry or a credential checklist. It is a continuum of care in which each specialist’s expertise protects the value of the other’s work. Accurate diagnosis makes surgery safer and more effective; skilled surgery delivers results that medical therapy alone cannot.

The right question is not “dermatologist or hair restoration specialist?” It is “where am I in the pathway, and who do I need right now?”

Next Steps: Finding Your Place in the Care Pathway

• For new or worsening hair loss: Begin with a dermatologic evaluation. Trichoscopy, and if needed, biopsy or bloodwork, will establish a clear diagnosis and identify any reversible or active conditions.
• For a confirmed structural diagnosis: Patients diagnosed with stable androgenetic alopecia, confirmed DPA, or a scarring alopecia that has been cleared after sustained quiescence should consult a dedicated hair restoration specialist to discuss surgical or cosmetic options.
• For candidates ready to explore restoration: Shapiro Medical Group offers consultations to discuss FUE, FUT, SMP, and supportive therapies once a diagnosis has confirmed candidacy. The team works alongside a patient’s dermatologist, whether the patient lives in Minnesota or is traveling from abroad.

The best outcomes come from treating hair loss as a coordinated, two-stage medical and surgical process, not a single decision made in isolation.